AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Identify the crucial factors when comparing indices, including coverage, weighting, and methodology. Use these pointers to sharpen your assessment.
16,969 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
As fuel costs climb, airline stocks stumble and investors reassess 2026 earnings prospects. This piece breaks down wh...
Palantir is moving beyond a services banner toward a durable AI-first platform. If the company scales its AI plumbing...
The SPDR S&P Semiconductor ETF jumps roughly 12% amid resilient AI-related demand, yet Intel remains a weakness in an...
A new wave in space tech is redefining how satellites connect the world. This guide explains why rocket shakes satell...
Forum Energy's latest earnings reveal how the company balances growth with cash flow in volatile markets. This guide ...
Thailand's central bank has flagged unusual stablecoin transfers as part of a broader crackdown on the grey economy. ...
A coordinated crackdown on outlaw motorcycle clubs is reshaping risk pricing in niche markets. Here’s how investors s...
Abbott Laboratories and Pfizer both delivered solid Q1 2026 numbers, yet the market sentiment diverged. Abbott slumpe...
Dragonfly Capital closes a $650 million fund to back early-stage crypto ventures as liquidity tightens and token pric...
SpaceX and Amazon share a blueprint for infrastructure growth, but their earnings paths diverge, forcing investors to...
A high-profile operation in Mexico ends with the death of a cartel leader, prompting a shelter-in-place advisory for ...